
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (date of earliest event reported): August 28, 2015

OPEXA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Texas
(State or other jurisdiction of
incorporation)

001-33004
(Commission File Number)

76-0333165
(IRS Employer Identification
No.)

2635 Technology Forest Blvd., The Woodlands, Texas
(Address of principal executive offices)

77381
(Zip Code)

Registrant's telephone number, including area code: **(281) 272-9331**
N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.07 Submission of Matters to a Vote of Security Holders

The Annual Meeting of Shareholders for Opexa Therapeutics, Inc. (“Opexa”) was held on August 28, 2015 (the “Annual Meeting”). Four proposals were submitted to shareholders as described in the 2015 Proxy Statement and were approved by shareholders at the Annual Meeting. The proposals and the results of the shareholder votes are as follows.

1.	For	Withheld	Broker Non-Votes	
Proposal to elect six directors for one-year terms:				
Timothy C. Barabe	12,503,559	957,541	25,588,136	
Hans-Peter Hartung	10,401,629	3,059,471	25,588,136	
Gail J. Maderis	12,324,939	1,136,161	25,588,136	
Michael S. Richman	12,496,172	964,928	25,588,136	
Scott B. Seaman	12,322,816	1,138,284	25,588,136	
Neil K. Warma	12,258,953	1,202,147	25,588,136	
2.	For	Against	Abstain	Broker Non-Votes
Proposal to approve an amendment to the Restated Certificate of Formation to increase the number of authorized shares of common stock to 150 million	30,436,939	8,216,038	396,259	0
3.	For	Against	Abstain	Broker Non-Votes
Proposal to approve an amendment to the Restated Certificate of Formation to effect a reverse stock split of the common stock, as determined by the Board of Directors in its discretion, of a ratio of not less than 1-for-4 and not more than 1-for-8	34,060,036	4,624,809	364,391	0
4.	For	Against	Abstain	Broker Non-Votes
Proposal to ratify the appointment of MaloneBailey, LLP as independent auditors for the fiscal year ending December 31, 2015	37,409,987	1,025,212	614,037	0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OPEXA THERAPEUTICS, INC.

Dated: September 3, 2015

By: /s/ Karthik Radhakrishnan

Karthik Radhakrishnan
Chief Financial Officer